Leung Kitty, Louca Emily, Coates Allan L
Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Ave, Toronto, ON, Canada.
Chest. 2004 Nov;126(5):1619-27. doi: 10.1378/chest.126.5.1619.
To evaluate differences between three new-generation nebulizers-Pari LC Star (Pari Respiratory Equipment; Mississauga, ON, Canada), AeroEclipse (Trudell Medical International, London, ON, Canada), and Halolite (Medic-Aid Limited, West Sussex, UK)-in terms of rate and amount of expected deposition as well as the consistency of the doses delivered.
The in vitro performance characteristics were determined and then coupled to the respiratory pattern of seven patients with cystic fibrosis (age range, 4 to 18 years) in order to calculate expected deposition. The Pari LC Star and AeroEclipse were characterized while being driven by the Pari ProNeb Ultra compressor (Pari Respiratory Equipment) for home use, and by a 50-psi medical air hospital source. The Halolite has its own self-contained compressor. Algorithms for the rate of output for the inspiratory flow were developed for each device. Patient flow patterns were divided into 5-ms epochs, and the expected deposition for each epoch was calculated from the algorithms. Summed over a breath, this allowed the calculation of the estimated deposition for each patient's particular pattern of breathing.
The rate of deposition was highest for the Pari LC Star and lowest for the Halolite. Rate of deposition was independent of respiratory pattern for the Pari LC Star and AeroEclipse, but proportional to respiratory rate for the Halolite. The differences between the Pari LC Star and AeroEclipse were less when driven by the 50-psi source. The AeroEclipse had the least amount of drug wastage. As designed, the Halolite delivered a predetermined amount of drug very accurately, whereas expected deposition when run to dryness of the other two devices had significant variations.
To minimize treatment time, the Pari LC Star would be best. To minimize drug wastage, the AeroEclipse would be best. To accurately deliver a specific drug dose, the Halolite would be best.
评估三款新一代雾化器——帕里LC之星(加拿大安大略省密西沙加市帕里呼吸设备公司)、航空日蚀(加拿大安大略省伦敦市特鲁德尔医疗国际公司)和哈洛莱特(英国西萨塞克斯郡医疗救助有限公司)——在预期沉积速率和沉积量以及给药剂量一致性方面的差异。
测定体外性能特征,然后结合7例囊性纤维化患者(年龄范围4至18岁)的呼吸模式,以计算预期沉积量。帕里LC之星和航空日蚀在由帕里ProNeb Ultra家用压缩机(帕里呼吸设备公司)驱动以及由50磅力/平方英寸的医用空气医院气源驱动时进行特性分析。哈洛莱特有其自带的压缩机。为每个设备开发了吸气流量输出速率的算法。将患者的气流模式划分为5毫秒的时间段,并根据算法计算每个时间段的预期沉积量。对一次呼吸进行汇总,从而能够计算出每位患者特定呼吸模式的估计沉积量。
帕里LC之星的沉积速率最高,哈洛莱特的最低。帕里LC之星和航空日蚀的沉积速率与呼吸模式无关,但哈洛莱特的沉积速率与呼吸频率成正比。由50磅力/平方英寸的气源驱动时,帕里LC之星和航空日蚀之间的差异较小。航空日蚀的药物浪费量最少。按照设计,哈洛莱特能非常精确地输送预定剂量的药物,而另外两款设备运行至干燥时的预期沉积量有显著差异。
为使治疗时间最短,帕里LC之星最佳。为使药物浪费最少,航空日蚀最佳。为准确输送特定药物剂量,哈洛莱特最佳。